Clinical trial
CMAB vs IMAB in Metastatic Prostate Cancer
NCT00255268 · AstraZeneca, Industry · Withdrawn
Key facts
| NCT number | NCT00255268 |
|---|---|
| Title | CMAB vs IMAB in Metastatic Prostate Cancer |
| Official title | Longitudinal, Randomized, Open and Prospective Clinical Trial to Evaluate the Efficacy of Continuous vs Intermittent Maximum Androgen Blockade (CMAB vs IMAB) With Goserelin-Bicalutamide Combination in the Treatment of Hormonal naïve With Metastatic Prostate Cancer |
| Lead sponsor | AstraZeneca, Industry |
| Status | Withdrawn |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Metastatic Prostate Cancer |
| Intervention type | Drug |
| Interventions | Goserelin, Bicalutamide |
| Enrollment | 15 |
| Start date | Aug 1, 2004 |
| First posted | Nov 18, 2005 |
| Last update posted | Aug 28, 2007 |
| Countries | Mexico |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: